Variants in the NR3C1 gene have been reported to contribute to: the risk for MDD [15]; antidepressants response [16]; metabolic traits or phenotypes, such as insulin resistance [17]; reduced risk for T2D in Cushing syndrome [18]; reduced risk for quantitative metabolic traits (e.g., fasting plasma glucose, glycated hemoglobin), in subjects stratified for the metabolic ineffective cortisone, a cortisol metabolite [19]; and increased risk for T2D in adults with decreased birth length [20]. This evidence concerns the gene NR3C1 and Cushing syndrome due to macronodular adrenal hyperplasia.